Early last year I wrote that women’s health represented one of the most underexplored, undercapitalized opportunities in the global economy — a market where the WEF and McKinsey had put a number on the prize: close the women’s health gap and add roughly $1 trillion to global GDP a year by 2040. The thesis was that smart capital would move toward that gap because the returns were sitting there unclaimed.

A year and a half on, the awareness has arrived. The capital mostly hasn’t.

We are living through a longevity boom. According to Longevity.Technology’s 2024 Annual Longevity Investment Report, investment in the sector more than doubled to $8.49 billion in 2024. Money is pouring into the science and consumer economy of aging well — diagnostics, supplements, hormone optimization, wearables, longevity clinics — and, as the Stanford Center on Longevity notes, investors are betting heavily that the sector can scale fast enough to capture it. Much of that capital is aimed at helping people who are already relatively healthy and relatively wealthy become marginally more optimized. That is a legitimate market.

But it is not the frontier.

Even within longevity, the highest returns aren’t in the exotic science. The World Economic Forum’s 2026 Longevity Dividend report found that three low-tech interventions — home safety improvements, hearing aid access, and physical activity programs — could unlock $5.8 trillion in healthcare savings by 2040.

And the most neglected basics of all belong to women. The real frontier is the vast, underserved base of demand — women whose basic health needs the system was never designed to meet, and, even more so, the billions in emerging markets for whom a first point of quality care does not yet exist. Women’s health captures only 6% of private healthcare investment, and companies focused exclusively on women’s health attract less than 1%.

The capital isn’t just too small. It’s aimed at the wrong targets, on two axes at once. By........

© Forbes